Associated Genetic Biomarkers
NUTM1 is altered in 0.37% of all cancers with lung adenocarcinoma, melanoma, skin squamous cell carcinoma, conventional glioblastoma multiforme, and breast invasive ductal carcinoma having the greatest prevalence of alterations .
The most common alterations in NUTM1 are NUTM1 Fusion (0.03%), NUTM1 P159L (0.06%), NUTM1 R203H (0.05%), NUTM1 S116L (0.05%), and NUTM1 R215H (0.04%) .
NUTM1 status serves as an inclusion eligibility criteria in 5 clinical trials, of which 0 are open and 5 are closed. Of the trials that contain NUTM1 status as an inclusion criterion, 4 are phase 1 (0 open) and 1 is phase 1/phase 2 (0 open).
Trials with NUTM1 status in the inclusion eligibility criteria most commonly target NUT midline carcinoma of the head and neck, breast carcinoma, malignant solid tumor, and NUT carcinoma .
The most frequent alterations to serve as inclusion eligibility criteria are NUTM1 Fusion, NUTM1 Expression, and NUTM1 Overexpression .
Molibresib, cudc-907, birabresib, cisplatin, and etoposide are the most frequent therapies in trials with NUTM1 as an inclusion criteria .
Significance of NUTM1 in Diseases
NUT Midline Carcinoma Of The Head And Neck +
NUTM1 is altered in 27.27% of NUT midline carcinoma of the head and neck patients .
NUTM1 is an inclusion criterion in 3 clinical trials for NUT midline carcinoma of the head and neck, of which 0 are open and 3 are closed. Of the trials that contain NUTM1 status and NUT midline carcinoma of the head and neck as inclusion criteria, 3 are phase 1 (0 open) .
Malignant Solid Tumor +
Breast Carcinoma +
NUT Carcinoma +
Non-Small Cell Lung Carcinoma +
NUTM1 is altered in 0.4% of non-small cell lung carcinoma patients .
NUTM1 is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NUTM1 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) .
Prostate Carcinoma +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.